We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+11.82%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$328M
AUM Growth
+$81.1M
Cap. Flow
+$76.2M
Cap. Flow %
23.2%
Top 10 Hldgs %
53.81%
Holding
97
New
24
Increased
8
Reduced
15
Closed
50

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.7M
2
ABT icon
Abbott
ABT
+$18.5M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$17.3M
4
CTLT
CATALENT, INC.
CTLT
+$13.9M
5
ARKK icon
ARK Innovation ETF
ARKK
+$13.4M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$12.1M
2
WST icon
West Pharmaceutical
WST
+$8.84M
3
APLS
Apellis Pharmaceuticals
APLS
+$8.36M
4
CLDX icon
Celldex Therapeutics
CLDX
+$7.85M
5
STVN icon
Stevanato
STVN
+$6.36M

Sector Composition

Rank Sector Weight
1 Healthcare 95.57%
2 Energy 0.07%
3 Real Estate 0.03%
4 Materials 0.02%
5 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
26
DELISTED
Astria Therapeutics
ATXS
$3.66M 1.11%
275,011
-376,319
-58% -$5.09M
AKRO
27
DELISTED
Akero Therapeutics
AKRO
$3.39M 1.03%
88,524
-40,327
-31% -$1.8M
XFOR icon
28
X4 Pharmaceuticals
XFOR
$391M
$3.37M 1.03%
129,283
+5,732
+5% +$168K
MDGL icon
29
Madrigal Pharmaceuticals
MDGL
$11.9B
$3.35M 1.02%
13,845
-12,541
-48% -$3.42M
VKTX icon
30
Viking Therapeutics
VKTX
$3.91B
$3.33M 1.01%
+200,000
New +$2.07M
BEAM icon
31
Beam Therapeutics
BEAM
$2.8B
$3.28M 1%
107,230
+25,212
+31% +$995K
PTGX icon
32
Protagonist Therapeutics
PTGX
$8.83B
$3.07M 0.93%
+133,452
New +$2.24M
RXDX
33
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$3.06M 0.93%
+28,470
New +$3.28M
ISEE
34
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$2.6M 0.79%
106,711
-136,368
-56% -$2.99M
ROIV icon
35
Roivant Sciences
ROIV
$25B
$2.54M 0.77%
+344,530
New +$2.84M
ETNB
36
DELISTED
89bio
ETNB
$2.39M 0.73%
+157,225
New +$2.05M
ALT icon
37
Altimmune
ALT
$589M
$2.23M 0.68%
528,814
+203,120
+62% +$2.41M
PRAX icon
38
Praxis Precision Medicines
PRAX
$8.9B
$2.01M 0.61%
165,890
+164,280
+10,204% +$6.93M
VRNA
39
DELISTED
Verona Pharma
VRNA
$1.96M 0.6%
+97,814
New +$2.11M
EOLS icon
40
Evolus
EOLS
$407M
$1.36M 0.41%
+160,269
New +$1.45M
FEMY icon
41
Femasys
FEMY
$9.09M
$137K 0.04%
6,324
+1,187
+23% +$27.3K
AM icon
42
Antero Midstream
AM
$10B
$117K 0.04%
11,114
-4,039
-27% -$43K
BTG icon
43
B2Gold
BTG
$5.46B
$75.2K 0.02%
+19,076
New +$71K
PGRE
44
DELISTED
Paramount Group
PGRE
$68.4K 0.02%
+15,008
New +$82.4K
ETRN
45
DELISTED
Equitrans Midstream Corporation Common Stock
ETRN
$58.6K 0.02%
+10,131
New +$64.9K
SWN
46
DELISTED
Southwestern Energy Company
SWN
$51.8K 0.02%
+10,357
New +$54.9K
UNIT
47
Uniti Group
UNIT
$2.35B
$40.4K 0.01%
11,370
-1,121
-9% -$5.95K
AHRT
48
AH Realty Trust
AHRT
$518M
– –
-14,573
Closed -$168K
AIV
49
Aimco
AIV
$381M
– –
-14,169
Closed -$101K
AMRX icon
50
Amneal Pharmaceuticals
AMRX
$5.89B
– –
-21,622
Closed -$43K
1
2
3 4

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q1 2023 Portfolio in Review

As of Q1 2023, Tri Locum Partners held 97 positions worth $328M, up 33% from $247M the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Tri Locum Partners deployed $76.2M of net new capital in Q1 2023, opening 24 new positions and adding to 8 existing holdings. Its largest new stake was Regeneron Pharmaceuticals: 43,389 shares worth $35.7M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 91% a quarter earlier, followed by Energy and Real Estate.

On the sell side, the largest reduction was West Pharmaceutical, an estimated $8.84M trimmed.

  • Tri Locum Partners's largest Q1 2023 buy was Regeneron Pharmaceuticals: 43,389 shares worth $35.7M.
  • Tri Locum Partners added most to Praxis Precision Medicines in Q1 2023, an estimated $6.93M increase.
  • Tri Locum Partners's biggest Q1 2023 reduction was West Pharmaceutical, cutting an estimated $8.84M.
  • Tri Locum Partners fully exited Ascendis Pharma A/S in Q1 2023, selling an estimated $12.1M.
  • Tri Locum Partners's ten largest holdings make up 54% of its $328M portfolio in Q1 2023.
  • Tri Locum Partners opened 24 new positions and closed 50 in Q1 2023.
  • Tri Locum Partners's portfolio value rose 33% quarter-over-quarter to $328M.

Based on Tri Locum Partners's 13F filing for Q1 2023, filed 15 May 2023.